The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors

Philippa Ellwood, M. Innes Asher, Nils E. Billo, Karen Bissell, Chen Yuan Chiang, Eamon M. Ellwood, Asma El-Sony, Luis García-Marcos, Javier Mallol, Guy B. Marks, Neil E. Pearce, David P. Strachan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation. GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.

Original languageEnglish
Article number1601605
JournalEuropean Respiratory Journal
Volume49
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Asthma
Hypersensitivity
Eczema
Rhinitis
Practice Management
Hospital Emergency Service
Age Groups
Parents

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The Global Asthma Network rationale and methods for Phase I global surveillance : prevalence, severity, management and risk factors. / Ellwood, Philippa; Asher, M. Innes; Billo, Nils E.; Bissell, Karen; Chiang, Chen Yuan; Ellwood, Eamon M.; El-Sony, Asma; García-Marcos, Luis; Mallol, Javier; Marks, Guy B.; Pearce, Neil E.; Strachan, David P.

In: European Respiratory Journal, Vol. 49, No. 1, 1601605, 01.01.2017.

Research output: Contribution to journalArticle

Ellwood, P, Asher, MI, Billo, NE, Bissell, K, Chiang, CY, Ellwood, EM, El-Sony, A, García-Marcos, L, Mallol, J, Marks, GB, Pearce, NE & Strachan, DP 2017, 'The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors', European Respiratory Journal, vol. 49, no. 1, 1601605. https://doi.org/10.1183/13993003.01605-2016
Ellwood, Philippa ; Asher, M. Innes ; Billo, Nils E. ; Bissell, Karen ; Chiang, Chen Yuan ; Ellwood, Eamon M. ; El-Sony, Asma ; García-Marcos, Luis ; Mallol, Javier ; Marks, Guy B. ; Pearce, Neil E. ; Strachan, David P. / The Global Asthma Network rationale and methods for Phase I global surveillance : prevalence, severity, management and risk factors. In: European Respiratory Journal. 2017 ; Vol. 49, No. 1.
@article{81d289253365413d8c5e346080b58afc,
title = "The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors",
abstract = "The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation. GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.",
author = "Philippa Ellwood and Asher, {M. Innes} and Billo, {Nils E.} and Karen Bissell and Chiang, {Chen Yuan} and Ellwood, {Eamon M.} and Asma El-Sony and Luis Garc{\'i}a-Marcos and Javier Mallol and Marks, {Guy B.} and Pearce, {Neil E.} and Strachan, {David P.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1183/13993003.01605-2016",
language = "English",
volume = "49",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - The Global Asthma Network rationale and methods for Phase I global surveillance

T2 - prevalence, severity, management and risk factors

AU - Ellwood, Philippa

AU - Asher, M. Innes

AU - Billo, Nils E.

AU - Bissell, Karen

AU - Chiang, Chen Yuan

AU - Ellwood, Eamon M.

AU - El-Sony, Asma

AU - García-Marcos, Luis

AU - Mallol, Javier

AU - Marks, Guy B.

AU - Pearce, Neil E.

AU - Strachan, David P.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation. GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.

AB - The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation. GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.

UR - http://www.scopus.com/inward/record.url?scp=85019002574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019002574&partnerID=8YFLogxK

U2 - 10.1183/13993003.01605-2016

DO - 10.1183/13993003.01605-2016

M3 - Article

C2 - 28077477

AN - SCOPUS:85019002574

VL - 49

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 1

M1 - 1601605

ER -